Genomictree Inc. (KOSDAQ:228760)
South Korea · Delayed Price · Currency is KRW 23,600
+400 (1.72%)
Sep 19, 2025, 3:30 PM KST
Genomictree Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Operating Revenue | 3,555 | 2,362 | 3,418 | 29,866 | 5,140 | 1,239 | Upgrade |
Other Revenue | - | - | 0 | - | - | - | Upgrade |
| 3,555 | 2,362 | 3,418 | 29,866 | 5,140 | 1,239 | Upgrade | |
Revenue Growth (YoY) | 74.43% | -30.89% | -88.55% | 481.09% | 314.87% | 339.89% | Upgrade |
Cost of Revenue | 3,053 | 3,108 | 3,720 | 4,891 | 2,641 | 1,193 | Upgrade |
Gross Profit | 502.29 | -745.56 | -301.62 | 24,974 | 2,499 | 46.03 | Upgrade |
Selling, General & Admin | 8,145 | 8,757 | 10,936 | 14,024 | 8,524 | 8,242 | Upgrade |
Research & Development | 4,100 | 4,942 | 4,366 | 5,446 | 2,812 | 3,510 | Upgrade |
Other Operating Expenses | 461.69 | 267.92 | 894.91 | 223.09 | 384.93 | 18.63 | Upgrade |
Operating Expenses | 13,276 | 14,568 | 17,002 | 22,569 | 12,354 | 12,455 | Upgrade |
Operating Income | -12,773 | -15,313 | -17,303 | 2,405 | -9,855 | -12,409 | Upgrade |
Interest Expense | -315.49 | -294.65 | -2,054 | -5,382 | -4,606 | -1,668 | Upgrade |
Interest & Investment Income | 3,366 | 3,361 | 4,829 | 3,610 | 4,147 | 1,783 | Upgrade |
Currency Exchange Gain (Loss) | -89.94 | 565.25 | -21.87 | 498.93 | 831.9 | 52.23 | Upgrade |
Other Non Operating Income (Expenses) | 286.16 | 468.31 | 817.71 | -4,682 | 112.85 | -217.75 | Upgrade |
EBT Excluding Unusual Items | -9,527 | -11,214 | -13,733 | -3,550 | -9,369 | -12,459 | Upgrade |
Gain (Loss) on Sale of Investments | 408.11 | 828.71 | -328.33 | -2,097 | -2,072 | 728.2 | Upgrade |
Gain (Loss) on Sale of Assets | -117.94 | -4.46 | - | -92.05 | 17.1 | 8.45 | Upgrade |
Other Unusual Items | - | - | 4,558 | 2,045 | - | - | Upgrade |
Pretax Income | -9,245 | -10,389 | -9,503 | -3,693 | -11,424 | -11,722 | Upgrade |
Income Tax Expense | 1.09 | 1.09 | -496.61 | 2,544 | 0.92 | 0.94 | Upgrade |
Earnings From Continuing Operations | -9,246 | -10,390 | -9,007 | -6,237 | -11,425 | -11,723 | Upgrade |
Minority Interest in Earnings | 141.29 | 148.02 | 250.69 | -393.43 | - | -71.83 | Upgrade |
Net Income | -9,105 | -10,242 | -8,756 | -6,631 | -11,425 | -11,795 | Upgrade |
Net Income to Common | -9,105 | -10,242 | -8,756 | -6,631 | -11,425 | -11,795 | Upgrade |
Shares Outstanding (Basic) | 24 | 24 | 22 | 21 | 21 | 20 | Upgrade |
Shares Outstanding (Diluted) | 24 | 24 | 27 | 21 | 21 | 20 | Upgrade |
Shares Change (YoY) | 3.29% | -9.92% | 26.28% | 1.68% | 3.30% | 4.57% | Upgrade |
EPS (Basic) | -379.45 | -428.94 | -390.66 | -315.89 | -553.38 | -590.16 | Upgrade |
EPS (Diluted) | -379.45 | -429.00 | -448.80 | -316.00 | -553.38 | -590.16 | Upgrade |
Free Cash Flow | -14,300 | -16,118 | -11,120 | 2,523 | -18,593 | -12,926 | Upgrade |
Free Cash Flow Per Share | -595.98 | -674.99 | -419.50 | 120.20 | -900.62 | -646.74 | Upgrade |
Gross Margin | 14.13% | -31.56% | -8.82% | 83.62% | 48.62% | 3.72% | Upgrade |
Operating Margin | -359.26% | -648.24% | -506.25% | 8.05% | -191.75% | -1001.62% | Upgrade |
Profit Margin | -256.07% | -433.57% | -256.17% | -22.20% | -222.28% | -952.10% | Upgrade |
Free Cash Flow Margin | -402.20% | -682.29% | -325.32% | 8.45% | -361.76% | -1043.37% | Upgrade |
EBITDA | -11,654 | -14,116 | -16,125 | 3,740 | -8,833 | -11,501 | Upgrade |
EBITDA Margin | - | - | - | 12.52% | -171.86% | - | Upgrade |
D&A For EBITDA | 1,119 | 1,198 | 1,178 | 1,335 | 1,022 | 907.92 | Upgrade |
EBIT | -12,773 | -15,313 | -17,303 | 2,405 | -9,855 | -12,409 | Upgrade |
EBIT Margin | - | - | - | 8.05% | -191.75% | - | Upgrade |
Advertising Expenses | - | 871.86 | 932.39 | 964.91 | 1,119 | 2,228 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.